Table 5.
Sensitivity analysis of randomised controlled trials on testosterone treatment → cardiorespiratory fitness outcomes meta-analysis
| N studies | N sample | SMD | (95% CI) | p Value for heterogeneity | |
|---|---|---|---|---|---|
| Fixed effects model | 5 | 136 | 0.21 | (−0.13 to 0.56) | 0.379 |
| Exclusion of one lower quality study (score <5) | 4 | 120 | 0.13 | (−0.27 to 0.54) | 0.315 |
| Exclusion of two placebo only control studies | 3 | 56 | 0.03 | (−0.60 to 0.66) | 0.269 |
| Exclusion of one study in men and women | 4 | 120 | 0.13 | (−0.27 to 0.54) | 0.315 |
| Exclusion of two longer duration study (≥12 weeks) | 3 | 103 | 0.27 | (−0.12 to 0.67) | 0.553 |
| Model using peak workload rather than peak VO2 outcomes | 5 | 241 | 0.27 | (0.01 to 0.52) | 0.741 |
| Model using 6MWT rather than peak VO2 outcomes | 4 | 184 | 0.10 | (−0.34 to 0.53) | 0.210 |
6MWT, 6 min walking test; N, number; SMD, standardised mean difference.